Trade Summary

1 month ago, Raha Samraat S., serving as Pres, CEO at Myriad Genetics Inc (MYGN), purchased 40,000 shares at $5.00 per share, for a total transaction value of $199,844.00. Following this transaction, Raha Samraat S. now holds 493,104 shares of MYGN.

This purchase represents a 9.00% increase in Raha Samraat S.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, March 9, 2026 and publicly disclosed via SEC Form 4 filing on Monday, March 9, 2026, meaning the disclosure happened on the same day as the trade.

Myriad Genetics Inc operates in the HEALTHCARE sector, specifically within the DIAGNOSTICS & RESEARCH industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.